Daniel Kerr

592 total citations
16 papers, 439 citations indexed

About

Daniel Kerr is a scholar working on Oncology, Dermatology and Epidemiology. According to data from OpenAlex, Daniel Kerr has authored 16 papers receiving a total of 439 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Dermatology and 4 papers in Epidemiology. Recurrent topics in Daniel Kerr's work include Cutaneous lymphoproliferative disorders research (6 papers), CAR-T cell therapy research (5 papers) and Fungal Infections and Studies (4 papers). Daniel Kerr is often cited by papers focused on Cutaneous lymphoproliferative disorders research (6 papers), CAR-T cell therapy research (5 papers) and Fungal Infections and Studies (4 papers). Daniel Kerr collaborates with scholars based in United States, Taiwan and South Korea. Daniel Kerr's co-authors include Julie O’Neal, Jason Chesney, Sucheta Telang, Brian F. Clem, Yoannis Imbert-Fernandez, Amy Clem, Rebecca Redman, Gilles Tapolsky, John O. Trent and Alden C. Klarer and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Daniel Kerr

16 papers receiving 428 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Kerr United States 8 231 204 171 60 48 16 439
Prasad Chaskar Switzerland 6 372 1.6× 187 0.9× 387 2.3× 26 0.4× 19 0.4× 8 600
Neal Fischbach United States 9 200 0.9× 88 0.4× 230 1.3× 31 0.5× 19 0.4× 21 499
Sidse Ørnbjerg Würtz Denmark 11 155 0.7× 235 1.2× 243 1.4× 41 0.7× 10 0.2× 14 465
Lise L. Christensen Denmark 11 569 2.5× 503 2.5× 153 0.9× 40 0.7× 46 1.0× 18 802
Barbara Martinoglio Italy 4 171 0.7× 98 0.5× 185 1.1× 31 0.5× 18 0.4× 5 396
Raj Bandaru United States 8 309 1.3× 142 0.7× 173 1.0× 46 0.8× 16 0.3× 10 539
Qiongyan Zou China 12 256 1.1× 255 1.3× 112 0.7× 9 0.1× 27 0.6× 35 441
Masaya Kai Japan 15 361 1.6× 177 0.9× 422 2.5× 17 0.3× 19 0.4× 35 698

Countries citing papers authored by Daniel Kerr

Since Specialization
Citations

This map shows the geographic impact of Daniel Kerr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Kerr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Kerr more than expected).

Fields of papers citing papers by Daniel Kerr

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Kerr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Kerr. The network helps show where Daniel Kerr may publish in the future.

Co-authorship network of co-authors of Daniel Kerr

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Kerr. A scholar is included among the top collaborators of Daniel Kerr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Kerr. Daniel Kerr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
Gurion, Ronit, Catherine Thiéblemont, Won Seog Kim, et al.. (2024). Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial. Blood. 144(Supplement 1). 3110–3110. 7 indexed citations
3.
Kerr, Daniel, David Lavie, Abraham Avigdor, et al.. (2024). First Data From Subcutaneous Epcoritamab + Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) for First-Line Diffuse Large B-Cell Lymphoma (DLBCL): EPCORE NHL-5. Clinical Lymphoma Myeloma & Leukemia. 24. S217–S217. 2 indexed citations
4.
Kasi, Pashtoon Murtaza, Nava Almog, Clinton Yam, et al.. (2023). RNA sequencing as a confirmatory assay and its impact on patient care in multiple cancer types.. Journal of Clinical Oncology. 41(16_suppl). e15058–e15058. 1 indexed citations
5.
Yun, Seongseok, Onyee Chan, Daniel Kerr, et al.. (2020). Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant. Blood Advances. 4(14). 3435–3442. 33 indexed citations
6.
Yun, Seongseok, Onyee Chan, Daniel Kerr, et al.. (2020). Survival Outcomes in Blastic Plasmacytoid Dendritic Cell Neoplasm By First-Line Treatment and Stem Cell Transplant. Blood. 136(Supplement 1). 15–15. 2 indexed citations
7.
Kerr, Daniel, Ling Zhang, & Lubomir Sokol. (2019). Blastic Plasmacytoid Dendritic Cell Neoplasm. Current Treatment Options in Oncology. 20(1). 9–9. 17 indexed citations
8.
Kerr, Daniel, Damian A. Laber, Nathan Visweshwar, & Michael Jaglal. (2018). Case Report: CEA Elevation Can Be a Marker of Increased Inflammation During Treatment with Oxaliplatin. Anticancer Research. 38(3). 1711–1713. 6 indexed citations
9.
Mushtaq, Sarah, et al.. (2018). A single-institution study of renal outcomes in patients receiving checkpoint inhibitors.. Journal of Clinical Oncology. 36(15_suppl). e15079–e15079. 1 indexed citations
10.
Kerr, Daniel & Lubomir Sokol. (2018). The advances in therapy of blastic plasmacytoid dendritic cell neoplasm. Expert Opinion on Investigational Drugs. 27(9). 733–739. 16 indexed citations
11.
Imbert-Fernandez, Yoannis, Brian F. Clem, Julie O’Neal, et al.. (2014). Estradiol Stimulates Glucose Metabolism via 6-Phosphofructo-2-kinase (PFKFB3). Journal of Biological Chemistry. 289(13). 9440–9448. 73 indexed citations
12.
Clem, Brian F., Julie O’Neal, Gilles Tapolsky, et al.. (2013). Targeting 6-Phosphofructo-2-Kinase (PFKFB3) as a Therapeutic Strategy against Cancer. Molecular Cancer Therapeutics. 12(8). 1461–1470. 215 indexed citations
13.
Kerr, Daniel & James L. Wittliff. (2011). A Five-Gene Model Predicts Clinical Outcome in ER+/PR+, Early-Stage Breast Cancers Treated with Adjuvant Tamoxifen. Hormones and Cancer. 2(5). 261–271. 15 indexed citations
14.
Wittliff, James L., et al.. (2008). Biosensors for Detecting Estrogen-like Molecules and Protein Biomarkers. Advances in experimental medicine and biology. 614. 315–322. 2 indexed citations
15.
Ledermann, JA, T.S. Maughan, Daniel Kerr, et al.. (1999). Preliminary results of a multicentre randomised trial comparing 3 chemotherapy regimens (De Gramont, Lokich and Raltitrexed) in metastatic colorectal cancer. UCL Discovery (University College London). 41 indexed citations
16.
Courtney, Richard M., et al.. (1977). Dental management of patients irradiated for oral cancer. Plastic & Reconstructive Surgery. 60(2). 297–297. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Prasad Chaskar Breakdown of academic impact, for papers by Neal Fischbach Breakdown of academic impact, for papers by Sidse Ørnbjerg Würtz Breakdown of academic impact, for papers by Lise L. Christensen Breakdown of academic impact, for papers by Barbara Martinoglio Breakdown of academic impact, for papers by Raj Bandaru Breakdown of academic impact, for papers by Qiongyan Zou Breakdown of academic impact, for papers by Masaya Kai
Rankless by CCL
2026